Company / Working Capital
Unicycive Therapeutics, Inc. Working Capital History
FY2022-FY2024 · Annual data · Source: SEC filings
At a glance
Latest annual filing availableLatest Working Capital
$6.8M
FY2024
5-year range
-$4.1M / $6.8M
FY2022-FY2024
Trend
+265.1%
vs FY2023
Sector context
Sector data unavailable
Latest sector comparison
What the data says
Working Capital changed +265% YoY in FY2024, a notable deviation from the 2-year average annual change of -140%.
Based on SEC 10-K filings.
$7M in FY2024.
Improved from -$640,000 to $7M over the past 2 years.
Working Capital over time
Growth rates
- 3-Year CAGR
- -
- 5-Year CAGR
- -
- 10-Year CAGR
- -
Key checks
Key Insights
- In FY2024, working capital increased 265.1% year-over-year.
Company context
Key Data Points
- Altman Z-Score -1.91 (distress zone, below 1.8 threshold)
- High earnings quality (cash-backed earnings)
Data sourced from SEC EDGAR filings. Not investment advice.
Annual data
| Year | Working CapitalValue | YoY GrowthYoY |
|---|---|---|
| FY2024 | $6.8M | +265.1% |
| FY2023 | -$4.1M | -546.1% |
| FY2022 | -$640.0K | - |
As of FY2024 · SEC 10-K · Updated Jun 28, 2026